Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Large Registry Finds Questionable PCI Procedures Before Surgery Remain Common

Executive Summary

Although most patients undergoing diagnostic coronary catheterization before noncardiac surgery do not have symptoms of coronary disease, about half of these patients are referred for revascularization despite the lack of evidence showing a benefit of revascularization in these patients according to data from a large national registry.

You may also be interested in...

AHA 2019: Conservative Approach Works As Well As Intervention For Stable Coronary Disease In ISCHEMIA Trial

The long-awaited results of the ISCHEMIA trial showed that patients with asymptomatic stable coronary disease get no apparent benefit from coronary intervention compared to a more conservative strategy with optimal medical management.

TCT 2017: ORBITA Ignites Controversy, Twitter Storm Over Stents, But Analysts Expect Little Impact

Results of the ORBITA trial, the first sham-controlled trial of percutaneous coronary intervention with drug-eluting stents in patients with stable angina found no difference in outcomes between the sham-control group and the group PCI-treated group. The results have triggered a lot of discussion and argument among physicians about the role of stents in stable angina patients, but securities analyst do not expect the results to have much impact on the drug-eluting stent market in the forseeable future.

At Muted J.P. Morgan, Focus Is Execution, But US Pricing Is Persistent Overhang

Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts